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OBJECTIVES: To assess whether prophylactic use of pegfilgastrim offers better
results in terms of health and expense associated with the incidence of febrile
neutropenia (FN) associated with myelosuppressive chemotherapy compared to
filgrastim in the IMSS METHODS: The measure of effectiveness was considered by
the incidence of NF in patients receiving myeloablative chemotherapy (Qt) and
received prophylaxis. According to literature, the prophylactic use of pegfilgrastim
reduced by 90% the incidence of FN and the prophylactic use of filgrastim reduces
by 39%. We constructed a decision tree, which considered the costs of treatment
and complications, including, costs of drugs, consultations, laboratory studies,
hospitalization and procedures. The incidence of FN is 20% when is used Qt.
RESULTS: If used as a prophylactic filgrastim, average cost of prophylactic treat-
ment over the complications of FN would be US$1982. However, if used as prophy-
lactic pegfilgrastim, based on their efficiency, the cost would be US$1421. If we use
as a prophylactic pegfilgrastim we will have savings of 28% compared with using
filgrastim. Following the trend of consumption of filgrastim in IMSS published by
the Federal Institute of Access to Public Information (IFAI) and assuming that 30%
of this consumption was used for prophylaxis for patients who received Qt, then
we can estimate that the number of prophylaxis given was about 15,000 cycles in
2009. This represents average savings of treatment (including complications of NF)
of 10 million USD, however if they had been treated with pegfilgrastim savings had
been for 18 million USD or 8 million USD more savings (86%) that using filgrastim
as prophylaxis. CONCLUSIONS: The prophylactic use of pegfilgatrim reduces costs
of care for cancer patients that are in Qt in the IMSS and provides a benefit to
patients.
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OBJECTIVES: In clinical studies, prophylactic HPV vaccines have demonstrated
high efficacy in the prevention of HPV infections, cervical intraepithelial neoplasia
(CIN) and genital warts. In Germany, routine HPV vaccination is recommended for
females aged 12 to 17 years. No transmission model reflecting the German health-
care setting which evaluates the cost-effectiveness of both the bivalent and quad-
rivalent HPV vaccines has been published yet. Hence, the objective of this study
was to determine the long-term impact of both available vaccines in addition to the
existing cervical cancer screening programme in Germany. METHODS: A mathe-
matical model simulating the transmission dynamics and the natural history of
HPV infection was developed. The age-structured model takes account of the oc-
currence of CIN, cervical cancer and genital warts and was calibrated using German
data on HPV prevalence and cancer statistics. Epidemiological and economic pa-
rameter estimates were obtained from published literature and supplemented by
expert interviews. The base-case analysis was conducted from a third-party payer
perspective and assumed a vaccination coverage of 50%, 10 years of sustained
vaccine protection followed by a period of waning immunity, costs of €474 for the
initial immunisation series and a 3% discount rate on future costs and health
effects. RESULTS: Compared with current screening practice, vaccination of 12-
year-old girls prevented additional 97,822 cervical cancer cases and 23,462 deaths
over a time horizon of 100 years. Under base-case assumptions, the discounted
ICERs were €57,413 per life-year gained and €37,198 per QALY gained for the biva-
lent vaccine, and €36,700 per life-year gained and €15,229 per QALY gained for the
quadrivalent vaccine. CONCLUSIONS: Considering the commonly accepted
threshold of €50,000 per QALY gained, routine HPV-vaccination of 12-year-old girls
is likely to be cost-effective in Germany. Additional protection against genital warts
in females and males by the quadrivalent vaccine improves the cost-effectiveness
ratio substantially.
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OBJECTIVES: To assess the cost-effectiveness of dasatinib 100 mg/day vs. imatinib
600 mg/day, imatinib 800 mg/day and versus nilotinib 800 mg/day in patients with
chronic myeloid leukaemia (CML) in the chronic phase of the disease, resistant to
prior therapy with imatinib 400 mg/day from the perspective of the Portuguese
National Health Service (NHS). METHODS: A cost-utility Markov model was devel-
oped by BMS for NICE appraisal and has been adapted to the Portuguese treatment
practice. Four health states were considered, three represented CML phases
(chronic, accelerate and blast) and the death state with one-month cycles. The
model was populated with efficacy data from clinical trials, resource utilization by
expert opinion, published quality of life data for CML laypersons in the UK and unit
prices from official 2010 price lists. A life-long, NHS perspective was used and
deterministic results were determined. A deterministic sensitivity analysis was
performed to test the robustness of the results. RESULTS: The results showed that
chronic phase CML patients resistant to standard dose imatinib gain on average
2.72 life-years, or 2.38 quality adjusted life-years, when treated with dasatinib 100
mg/day compared with imatinib 600 mg/day or compared to imatinib 800 mg/day
and on average 0.53 life-years, or 0.47 quality adjusted life-years compared to ni-
lotinib 800 mg/day. The incremental cost per quality adjusted life year gained
(QALY) amounts to €39,941 when dasatinib 100 mg/day is compared with imatinib
600 mg/day, and to €14,470 when compared to imatinib 800 mg/day and to €29,422
when compared to nilotinib during a lifetime period. CONCLUSIONS: The results
indicate that dasatinib is a cost-effective option in CML patients resistant to stan-
dard-dose imatinib in Portugal in comparison with high-dose imatinib and nilo-
tinib.
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OBJECTIVES: Degarelix is the first gonadotrophin-releasing hormone (GnRH) an-
tagonist to be launched in the UK for first-line treatment of advanced prostate
cancer. The aim of this evaluation was to predict long-term clinical and economic
outcomes from treatment with degarelix compared to treatment with goserelin,
standard current practice, from the perspective of NHS Scotland.METHODS: Anal-
yses were conducted using a 20 year semi-Markov (cohort health-state transition)
cost-utility model which was recently submitted to and accepted by the Scottish
Medical Consortium (SMC). The model considers two patient groups – the inten-
tion-to-treat population (ITT) of patients with hormone-responsive prostate cancer
in whom treatment with androgen-deprivation therapy is indicated and who
would be prescribed a LHRH agonist and a high-risk population with a baseline PSA
level 20ng/ml. Probabilistic and deterministic sensitivity analyses were con-
ducted to assess uncertainty in the model. RESULTS: The key benefit of treatment
with degarelix comes from keeping patients in the first-line treatment state for
longer, incurring less time and costs in the later more costly and lower utility
non-hormonal therapy state. At NHS list-price degarelix is estimated to dominate
treatment with goserelin within both populations with a saving of £271 and QALY
gain of 0.46 in the ITT population. Probabilistic sensitivity analyses show that de-
garelix is likely to be cost-effective (at a willingness-to-pay of £500 per QALY) in
100% of cases. CONCLUSIONS: The economic analysis shows that degarelix not
only provides a better patient outcome but is also less costly than goserelin over a
lifetime of treatment. It is rare for a new treatment to predict dominance over
existing therapies – only 18% of SMC submissions up to 2011 have predicted dom-
inance. In addition degarelix shows a large gain in quality of life (almost half a year
in full health) even when a conservative assumption of no increase in survival is
applied.
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OBJECTIVES: MM is the second most common haematological malignancy. With
the recent introduction of new agents, survival has greatly improved. This study
aimed to assess the cost-effectiveness of bortezomib (BOR) vs. dexamethasone
(DEX) as second-line treatment of RRMM. Lenalidomide in combination with dexa-
methasone (LENDEX) was also considered in a secondary analysis.METHODS:An
area under the curve decision-analytic model was developed, containing three
health states: “pre-progression”, “post-progression” and “dead”. Survival analyses
of the APEX trial (BOR vs. DEX) were used to estimate the transition probabilities by
line of treatment. As 71% of patients randomised to DEX crossed over to BOR, the
hazard ratios (HR) were adjusted for crossovers (progression-free survival [PFS]:
0.56; overall survival [OS]: 0.59). HRs for LENDEX vs. DEX (PFS: 0.35; OS: 0.71) were
retrieved from the MM-09/10 trials (not adjusted for 47.6% cross-over or line of
treatment). Treatment schedule, compliance rate and adverse events (AEs) rates
were retrieved from the above clinical trials, while utility weights were retrieved
from the published literature. The model runs over patients’ lifetime, and discount
rate of 3.5% was applied to costs and QALYs and assumptions around level of vial
sharing for bortezomib were investigated. RESULTS: BOR was associated with an
incremental effectiveness of 1.56 life years gained (LYG) and 0.86 QALYs per patient
compared to DEX, while LENDEX was found to be less effective (-0.64 LYG, -0.28
QALYs) than BOR. Scenario analyses showed BOR is cost-effective in most cases
when compared to DEX, while LENDEX was dominated by BOR. The results were
sensitive to treatment effect on survival. CONCLUSIONS: The model suggests that
BOR is a cost-effective option for treating RRMM in the UK.
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